Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data.


Journal

BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488

Informations de publication

Date de publication:
22 01 2020
Historique:
entrez: 24 1 2020
pubmed: 24 1 2020
medline: 6 2 2020
Statut: epublish

Résumé

To assess the magnitude and duration of any hypothesised protective effect of household exposure to a child with varicella on the relative incidence of herpes zoster in adults. Self controlled case series. UK general practices contributing to Clinical Practice Research Datalink. 9604 adults (≥18 years) with a diagnosis of herpes zoster (in primary care or hospital records) between 1997 and 2018, who during their observation period lived with a child (<18 years) with a diagnosis of varicella. Relative incidence of herpes zoster in the 20 years after exposure to a child with varicella in the household compared with baseline time (all other time, excluding the 60 days before exposure). 6584 of the 9604 adults with herpes zoster (68.6%) were women. Median age of exposure to a child with varicella was 38.3 years (interquartile range 32.3-48.8 years) and median observation period was 14.7 (11.1-17.7) years. 4116 adults developed zoster in the baseline period, 433 in the 60 days before exposure and 5055 in the risk period. After adjustment for age, calendar time, and season, strong evidence suggested that in the two years after household exposure to a child with varicella, adults were 33% less likely to develop zoster (incidence ratio 0.67, 95% confidence interval 0.62 to 0.73) compared with baseline time. In the 10-20 years after exposure, adults were 27% less likely to develop herpes zoster (0.73, 0.62 to 0.87) compared with baseline time. A stronger boosting effect was observed among men than among women after exposure to varicella. The relative incidence of zoster was lower in the periods after exposure to a household contact with varicella, with modest but long lasting protective effects observed. This study suggests that exogenous boosting provides some protection from the risk of herpes zoster, but not complete immunity, as assumed by previous cost effectiveness estimates of varicella immunisation.

Identifiants

pubmed: 31969318
doi: 10.1136/bmj.l6987
pmc: PMC7190015
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

l6987

Subventions

Organisme : British Heart Foundation
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 201440/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205039/Z/16/Z
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR/CS/010/014
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S003940/1
Pays : United Kingdom

Informations de copyright

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. AF has research funding (related to meningococcal carriage) paid to the University of Bristol from GSK. RM reports grants from GSK and from Merck for a study on chickenpox epidemiology.

Références

Clin Infect Dis. 2019 Jul 2;69(2):341-344
pubmed: 30496358
Proc Biol Sci. 2015 Apr 7;282(1804):20142509
pubmed: 25761709
J Infect Dis. 2002 Oct 15;186 Suppl 1:S91-8
pubmed: 12353193
Epidemiol Infect. 2017 Oct;145(13):2678-2682
pubmed: 28853391
Proc R Soc Med. 1965 Jan;58:9-20
pubmed: 14267505
Vaccine. 2017 Jan 23;35(4):680-686
pubmed: 28007397
Mayo Clin Proc. 2011 Feb;86(2):88-93
pubmed: 21220354
Epidemiol Infect. 2000 Dec;125(3):651-69
pubmed: 11218215
Cochrane Database Syst Rev. 2014 Jun 23;(6):CD001833
pubmed: 24954057
Clin Vaccine Immunol. 2014 Mar;21(3):417-26
pubmed: 24429070
Hum Vaccin Immunother. 2018;14(11):2632-2635
pubmed: 30059639
Bull World Health Organ. 2014 Aug 1;92(8):593-604
pubmed: 25177074
Stat Med. 2006 May 30;25(10):1768-97
pubmed: 16220518
BMJ. 2016 Sep 12;354:i4515
pubmed: 27618829
N Engl J Med. 2000 Mar 2;342(9):635-45
pubmed: 10699164
Elife. 2015 Jul 11;4:
pubmed: 26259874
Sci Rep. 2017 Apr 24;7(1):1077
pubmed: 28439065
MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30; quiz CE2-4
pubmed: 18528318
BMJ Open. 2014 Jun 10;4(6):e004833
pubmed: 24916088
Vaccine. 2009 Feb 5;27(6):882-7
pubmed: 19071175
J Infect Dis. 2014 Jul 15;209 Suppl 3:S120-6
pubmed: 24966192
Lancet. 2002 Aug 31;360(9334):678-82
pubmed: 12241874
Drugs Aging. 2010 Nov 1;27(11):885-93
pubmed: 20964462
Eur J Epidemiol. 2019 Jan;34(1):91-99
pubmed: 30219957
Vaccine. 2002 Jun 7;20(19-20):2500-7
pubmed: 12057605
BMJ. 2014 May 13;348:g2911
pubmed: 25134101
BMC Infect Dis. 2019 Feb 6;19(1):126
pubmed: 30727971
BMC Public Health. 2015 May 05;15:466
pubmed: 25940080
Stat Methods Med Res. 2009 Feb;18(1):7-26
pubmed: 18562396
Clin Infect Dis. 2019 Sep 27;69(8):1329-1338
pubmed: 30590491
Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26
pubmed: 17143845
Epidemiol Infect. 1992 Jun;108(3):513-28
pubmed: 1318219
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Arch Intern Med. 1995 Aug 7-21;155(15):1605-9
pubmed: 7618983
Ann Epidemiol. 2016 Jun;26(6):441-446.e3
pubmed: 27180114
Expert Rev Vaccines. 2017 Aug;16(8):833-843
pubmed: 28644696
PLoS One. 2013 Jun 21;8(6):e66485
pubmed: 23805224
Clin Infect Dis. 2010 Sep 1;51(5):525-30
pubmed: 20642353
Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):443-51
pubmed: 15898131
Am J Epidemiol. 2016 Apr 15;183(8):765-73
pubmed: 26994062

Auteurs

Harriet Forbes (H)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK harriet.forbes@lshtm.ac.uk.

Ian Douglas (I)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.

Adam Finn (A)

Bristol Children's Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Judith Breuer (J)

UCL Division of Infection and Immunity Wing 1.3, London, UK.

Krishnan Bhaskaran (K)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.

Liam Smeeth (L)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.

Simon Packer (S)

Field Epidemiology Services, Public Health England Bristol, Bristol, UK.

Sinéad M Langan (SM)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.

Kathryn E Mansfield (KE)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.

Robin Marlow (R)

Bristol Children's Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Heather Whitaker (H)

Statistics, Modelling and Economics Department, Data and Analytical Sciences, National Infection Service, Public Health England Colindale, London, UK.

Charlotte Warren-Gash (C)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH